Weekly Low-Dose Carboplatin and Paclitaxel in the Treatment of Recurrent Ovarian and Peritoneal Cancer
- 1 January 2003
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 88 (1) , 51-57
- https://doi.org/10.1006/gyno.2002.6859
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Hypersensitivity Reactions to Carboplatin Administration Are Common but Not Always Severe: A 10-Year ExperienceOncology, 2001
- Weekly Dosing of Carboplatin Increases Risk of Allergy in ChildrenJournal of Pediatric Hematology/Oncology, 2001
- Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effectsInternational Journal of Gynecologic Cancer, 2001
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian CancerGynecologic Oncology, 2001
- Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian CancerGynecologic Oncology, 1999
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimenEuropean Journal Of Cancer, 1994
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Reporting results of cancer treatmentCancer, 1981